Viking Therapeutics (DE:1VT)
FRANKFURT:1VT
1VT Stock Chart & Stats
€29.12
-€0.26(-0.65%)
At close: 4:00 PM EST
€29.12
-€0.26(-0.65%)
Day’s Range― - ―
52-Week Range€16.40 - €39.10
Previous CloseN/A
Volume0.00
Average Volume (3M)262.00
Market Cap
€3.43B
Enterprise Value€3.79B
Total Cash (Recent Filing)€705.74M
Total Debt (Recent Filing)€137.00K
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Apr 29, 2026EPS Estimate
-0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.20
Shares Outstanding115,554,300
10 Day Avg. Volume334
30 Day Avg. Volume262
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)6.20
Price to Sales (P/S)0.00
P/FCF Ratio-14.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€75.71Price Target Upside160.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-3.67
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash Runway / FinancingCompany's cash balance is expected to fund completion of the subcutaneous Phase 3 study, the maintenance dosing study, and initiation of the oral Phase 3 program, lowering near-term financing risk.
Clinical Development ProgressRegulatory clearance to advance the oral VK2735 directly to a late-stage trial after positive Phase II results shortens the pathway to pivotal data and could enable earlier separate regulatory filings for the oral program.
Commercial Preparedness And Market AccessHiring of a chief commercial officer with decades of cardiometabolic commercialization experience, together with planned direct-to-consumer, employer-based, and alternative PBM channel strategies, strengthens readiness for product launch and potential patient reach.
Bears Say
Clinical Trial Dependency RiskAnalyst reliance on the maintenance dosing trial outcome creates binary risk in the investment case, where unfavorable trial results could materially alter valuation and sentiment.
Financial Performance And Funding RiskRising research and development spending has widened losses, increasing financial pressure and raising the likelihood of future capital raises or equity dilution.
Manufacturing And Competitive BarriersManufacturing complexities and intense competition in the obesity and GLP-1 market represent significant long-term barriers that could limit market share even if clinical data are favorable.
Viking Therapeutics News
1VT FAQ
What was Viking Therapeutics’s price range in the past 12 months?
Viking Therapeutics lowest stock price was €16.40 and its highest was €39.09 in the past 12 months.
What is Viking Therapeutics’s market cap?
Viking Therapeutics’s market cap is €3.43B.
When is Viking Therapeutics’s upcoming earnings report date?
Viking Therapeutics’s upcoming earnings report date is Apr 29, 2026 which is in 33 days.
How were Viking Therapeutics’s earnings last quarter?
Viking Therapeutics released its earnings results on Feb 11, 2026. The company reported -€1.196 earnings per share for the quarter, missing the consensus estimate of -€0.771 by -€0.425.
Is Viking Therapeutics overvalued?
According to Wall Street analysts Viking Therapeutics’s price is currently Undervalued.
Does Viking Therapeutics pay dividends?
Viking Therapeutics does not currently pay dividends.
What is Viking Therapeutics’s EPS estimate?
Viking Therapeutics’s EPS estimate is -0.87.
How many shares outstanding does Viking Therapeutics have?
Viking Therapeutics has 115,554,300 shares outstanding.
What happened to Viking Therapeutics’s price movement after its last earnings report?
Viking Therapeutics reported an EPS of -€1.196 in its last earnings report, missing expectations of -€0.771. Following the earnings report the stock price went up 15.306%.
Which hedge fund is a major shareholder of Viking Therapeutics?
Currently, no hedge funds are holding shares in DE:1VT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viking Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€75.71 (160.00% Upside)
€75.71 (160.00% Upside)
Blogger Sentiment
Bullish
DE:1VT Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $11.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 83%
Bearish news 17%
Bearish news 17%
Technicals
SMA
Positive
20 days / 200 days
Momentum
30.03%
12-Months-Change
Fundamentals
Return on Equity
-48.04%
Trailing 12-Months
Asset Growth
-21.20%
Trailing 12-Months
Company Description
Viking Therapeutics
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
1VT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial clinical and operational progress: compelling Phase II efficacy for both subcutaneous (up to 14.7%) and oral (up to 12.2%, with 80% ≥10% responders), initiation and fast enrollment of Phase III programs, completion of auto-injector bioequivalence enabling device rollout, a completed maintenance study enrollment with results expected Q3 2026, a manufacturing agreement to support commercialization, and expansion of the pipeline with an amylin agonist. Offsetting these positives are sharply higher R&D expenses and widening net losses (large YoY increases), a ~22% decline in cash year-over-year, and a projected quarterly burn of $60M–$90M, alongside marketplace and reimbursement uncertainties. On balance, the operational and clinical milestones materially outweigh the financial and market risks presented on the call.View all DE:1VT earnings summaries1VT Stock 12 Month Forecast
Average Price Target
€75.71
▲(160.00% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Xenon
―
Scholar Rock Holding
―
Immunovant
―
NewAmsterdam Pharma Company
―
Options Prices
Currently, No data available
---